Trending

Argenx

J&J backs out of $1.6bn blood cancer antibody alliance with Argenx

J&J backs out of $1.6bn blood cancer antibody alliance with Argenx

Belgian biotech Argenx has lost its development partner for acute myeloid leukaemia antibody cusatuzumab, after Johnson & Johnson

X

J&J backs out of $1.6bn blood cancer antibody alliance with Argenx

https://pharmaphorum.com/news/jj-backs-out-of-1-6bn-blood-cancer-antibody-alliance-with-argenx/

AbbVie takes option on Argenx’s cancer immunotherapy

AbbVie takes option on Argenx’s cancer immunotherapy

ARGX-115 is still in preclinical development

X

AbbVie takes option on Argenx’s cancer immunotherapy

https://pharmaphorum.com/news/abbvie-takes-option-on-argenxs-cancer-immunotherapy/

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com